Loading…
Loading…
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas Expands Fortrea's early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions Strengthens Fortrea's end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation Supports Fortrea's growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company's ability to create long-term value for shareholders Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials.
Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential for a small-cap rebound if the 10-year Treasury yield peaks around their year-end forecast of 5%. I highlight three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000's recent high, defying the index's broader weakness.
Fortrea (NASDAQ: FTRE - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Institutional and Insider Ownership 6.7% of MindWalk shares are
Ausbil Investment Management Ltd trimmed its position in Fortrea Holdings Inc. (NASDAQ: FTRE) by 25.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,704 shares of the company's stock after selling 58,122 shares during the quarter.
Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) reached a new 52-week high during trading on Tuesday. The company traded as high as $21.81 and last traded at $22.1050, with a volume of 16613 shares traded. The stock had previously closed at $21.11. Analysts Set New Price Targets Several equities analysts have recently issued reports
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.